Drugs /
tremelimumab
Back to Drugs List
Associated Genetic Biomarkers
Overview
Clinical Trials
Tremelimumab has been investigated in 85 clinical trials, of which 68 are open and 17 are closed. Of the trials investigating tremelimumab, 2 are early phase 1 (2 open), 16 are phase 1 (9 open), 19 are phase 1/phase 2 (18 open), 41 are phase 2 (32 open), 6 are phase 3 (6 open), and 1 is no phase specified (1 open).
EGFR Exon 19 Deletion, EGFR L858R, and EGFR A763_Y764insFQEA are the most frequent biomarker inclusion criteria for tremelimumab clinical trials.
Non-small cell lung carcinoma, breast carcinoma, and fallopian tube carcinoma are the most common diseases being investigated in tremelimumab clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.